Explore the potential of protein design with the new deep learning approach from Chongqing University to enhance binding ...

While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is ...

Learn how radiopharmaceuticals are transforming nuclear medicine and cancer therapy through targeted diagnostics and ...

Forget the buzzwords – SLAS 2025 showed what’s genuinely driving progress in drug discovery: usable AI, collaborative platforms and tools that solve real problems. This year, the focus wasn’t on bold ...

Explore how multimodal AI is transforming drug development by integrating diverse data sources to accelerate discovery.

Cell and gene therapy is rapidly transforming the treatment of complex diseases, yet scaling production efficiently remains a challenge. Dr Tia Harmon from PHC Corporation of North America explores ...

The partnership allows for the further development of AI-designed RNA-targeted therapies for a range of diseases. Creyon Bio, Inc. (Creyon) has announced a landmark global licensing and multi-target ...

Huntington’s disease remains a major challenge, but allele-selective gene editing offers new hope. By targeting only the mutant gene, this approach could provide a one-time, durable treatment. Life ...

Judy Ashworth, CMO of Novadip Biosciences, shares her journey in advancing treatments for rare paediatric conditions and championing diversity in STEM. Drug Target Review sat down with Judy Ashworth, ...

What if vaccines could train your immune system to eliminate infections at the source? Find out how Gylden Pharma’s gold nanoparticle platform delivers targeted T cell immunity – providing a precise ...

Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies. As our understanding ...